Philadelphia, PA - Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items. Studies to date on phthalates have been inconsistent, with some linking exposure to these chemicals to hormone disruptions, birth defects, asthma, and reproductive problems, while others have found no significant association between exposure and adverse effects.

A new report by Korean scientists, published by Elsevier in the November 15th issue of Biological Psychiatry, adds to the potentially alarming findings about phthalates. They measured urine phthalate concentrations and evaluated symptoms of attention-deficit/hyperactivity disorder (ADHD) using teacher-reported symptoms and computerized tests that measured attention and impulsivity.

They found a significant positive association between phthalate exposure and ADHD, meaning that the higher the concentration of phthalate metabolites in the urine, the worse the ADHD symptoms and/or test scores.

Senior author Yun-Chul Hong, MD, PhD, explained that 'these data represent the first documented association between phthalate exposure and ADHD symptoms in school-aged children.' John Krystal, MD, the Editor of Biological Psychiatry, also commented: 'This emerging link between phthalates and symptoms of ADHD raises the concern that accidental environmental exposure to phthalates may be contributing to behavioral and cognitive problems in children. This concern calls for more definitive research.'
The U.S. Centers for Disease Control and Prevention, in the Summary of their 2005 Third National Report on Human Exposure to Environmental Chemicals, state that 'very limited scientific information is available on potential human health effects of phthalates at levels' found in the U.S. population. Although this study was performed in a Korean population, their levels of exposure are likely comparable to a U.S. population.

The current findings do not prove that phthalate exposure caused ADHD symptoms. However, these initial findings provide a rationale for further research on this association.

# # #

Notes to Editors:
The article is 'Phthalates Exposure and Attention-Deficit/Hyperactivity Disorder in School-Age Children' by Bung-Nyun Kim, Soo-Churl Cho, Yeni Kim, Min-Sup Shin, Hee-Jeong Yoo, Jae-Won Kim, Young Hee Yang, Hyo-Won Kim, Soo-Young Bhang, and Yun-Chul Hong. B-N Kim, S-C Cho, Y Kim, M-S Shin, J-W Kim, Y H Yang, and H-W Kim are affiliated with the Division of Child & Adolescent Psychiatry, Department of Psychiatry and Institute of Human Behavioral Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. H-J Yoo is from the Department of Psychiatry, Seoul National University Bundang Hospital, Seong-nam, Republic of Korea. Y-C Hong is with the Department of Preventive Medicine, Seoul National University College of Medicine and Institute of Environmental Medicine, SNUMRC, Seoul, Republic of Korea. S-Y Bhang is affiliated with the Department of Psychiatry, Ulsan University Hospital, Ulsan, Republic of Korea. The article appears in Biological Psychiatry, Volume 66, Issue 10 (November 15, 2009), published by Elsevier.

The authors' disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, M.D. is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available at http://journals.elsevierhealth.com/webfiles/images/journals/bps/Biological_Psychiatry_Editorial_Disclosures_08_01_09.pdf.

Full text of the article mentioned above is available upon request. Contact Jayne M. Dawkins at ja.dawkins@elsevier.com to obtain a copy or to schedule an interview.

About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.

Biological Psychiatry is ranked 4th out of the 101 Psychiatry titles and 14th out of 219 Neurosciences titles on the 2008 ISI Journal Citations Reports® published by Thomson Scientific.

About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

— WebWireID108235 —

The increased computerization in U.S. hospitals hasn't made them cheaper or more efficient, Harvard researchers say, although it may have modestly improved the quality of care for heart attacks.

The findings, published in today's [Friday's] online edition of The American Journal of Medicine, contradict claims by President Obama and many lawmakers that health information technology (health IT), including electronic medical records, will save billions and help make reform affordable.

"Our study finds that hospital computerization hasn't saved a dime, nor has it improved administrative efficiency," said lead author Dr. David Himmelstein, associate professor at Harvard Medical School and former director of clinical computing at Cambridge Hospital in Massachusetts. "Claims that health IT will slash costs and help pay for the reforms being debated in Congress are wishful thinking."

The study uses data from the most extensive survey ever undertaken of hospital computerization. Data from approximately 4,000 hospitals for the years 2003 to 2007, including those on a list of the "100 Most Wired," were analyzed for evidence of increased quality, cost savings or improvements in administrative efficiency.

The data came from the authoritative Healthcare Information and Management Systems Society (HIMSS) Analytics annual survey of hospital computerization; Medicare Cost Reports that virtually all hospitals submit annually to the Centers for Medicare and Medicaid Services (CMS); and the 2008 Dartmouth Health Atlas, which compiles CMS data on costs and quality of care.

Although the researchers found that U.S. hospitals increased their computerization between 2003 and 2007, they found no indication that health IT lowered costs or streamlined administration, even in the "most wired" institutions. While U.S. hospital administrative costs increased slightly, from 24.4 percent in 2003 to 24.9 percent in 2007, hospitals that computerized most rapidly actually had the largest increases in administrative costs. (By way of comparison, older studies have estimated administrative costs in Canadian hospitals at 12.9 percent).

The study found no evidence of lagged effects, e.g. lower costs in 2007 resulting from information technology introduced in 2003.

Modest quality gains were noted in the treatment of heart attacks (acute myocardial infarction) in more-computerized hospitals, but even these small improvements may merely represent better documentation rather than actual gains to patients.

Himmelstein said a report from the Congressional Budget Office in 2008 signed by Peter Orszag, now Obama's budget director, expressed skepticism about claims by the RAND Corp. and others that health IT could generate $80 billion annually in savings.

"Part of the CBO's skepticism was based on the limited information available to the RAND study and similar studies," Himmelstein said. "But this new, detailed, national survey of diverse hospitals shows such doubts are well-founded. Information technology can't rescue us from our national health care crisis."

Dr. Steffie Woolhandler, professor of medicine at Harvard and study co-author, said several factors may explain why health IT has failed to reduce administrative costs.

"Any savings may have been offset by the costs of purchasing and running new computer systems," she said. "In addition, most software is designed around the accounting and billing needs of hospitals, not the clinical side."

She noted that a computer success story in recent years has been at the Veterans Administration, where global budgets eliminate most billing and internal cost accounting, allowing physicians to focus instead on delivering care.

"The VA system now has our nation's highest quality and patient approval ratings," Woolhandler said. "Congress should take note: to get the most benefit from our health care dollars and from health IT, we should adopt a single-payer, Medicare-for-all program. Nothing short of that will allow us to reap the full potential of computerization or to provide comprehensive, quality and affordable care to all."

******
"Hospital computing and the costs and quality of care: a national study," David U. Himmelstein, M.D., Adam Wright, Ph.D., and Steffie Woolhandler, M.D., M.P.H., The American Journal of Medicine, Nov. 20, 2009 (online).

Physicians for a National Health Program (www.pnhp.org) is an organization of 17,000 doctors who advocate for single-payer national health insurance. To contact a physician-spokesperson near you, visit www.pnhp.org/stateactions or call (312) 782-6006.

— WebWireID108231 —

Every holiday season, millions of Americans travel through the nation's airports, seaports, and train stations to spend time with loved ones. Special holiday get-togethers – and traveling itself – bring people close together but also provide an ideal way for illness to spread. To help travelers avoid the flu this holiday season, the Centers for Disease Control and Prevention today launched its largest ever public awareness campaign about staying healthy while traveling.

'The holidays are one of the busiest travel times of the year,' said Anne Schuchat, M.D., director of CDC's National Center for Immunization and Respiratory Diseases. 'People are in close contact – whether they're on a plane, train, ship or just visiting with loved ones. This campaign provides practical advice to help travelers prepare for their trips and stay healthy during their holiday travel.'

CDC is urging people to take the following steps when planning their travel and to stay informed about what to do if they get sick while they're gone, including:

* Traveling only when they are feeling well
* Getting vaccinated for flu (both seasonal flu and 2009 H1N1 if they are in a priority group)
* Washing hands often
* Covering coughs and sneezes with a tissue or sleeve

'We know that flu – and specifically H1N1 this year – is a big concern for people, but flu shouldn't ruin the holidays,' Dr. Schuchat said. 'By practicing a little prevention, people can enjoy their holidays and stay well at the same time.'

CDC developed the campaign in response to the emergence in April of the 2009 H1N1 flu pandemic. Since then, flu has spread throughout the country and around the world. In the United States, it has accounted for millions of cases and more than 4,000 deaths since April.

CDC launched the campaign at a joint event with Homeland Security Secretary Janet Napolitano today in Washington, D.C. The campaign will run through the holiday season and use a variety of media, including informational posters at major airports, ports of entry and border crossings; national radio and print advertising; and social media and online outreach. CDC will also partner with local health departments, travel professionals, health care professionals, and colleges and universities to further educate the public. Campaign themes include 'Prevention can be Travel-Sized' and 'Stop, Wash and Go.'

For more information about the CDC Travelers' Health campaign, recommendations regarding travel, visit http://wwwnc.cdc.gov/travel/content/novel-h1n1-flu.aspx. For more information about the H1N1 virus, visit http://www.flu.gov.

— WebWireID108219 —

Dell announced a Mobile Clinical Computing (MCC) solution that is designed to eliminate the traditional trade-offs hospitals face between making patient information available to medical staff at the point of care and securing it in the data center to promote compliance with HIPAA regulations.

Data security is a legitimate concern for hospitals and patients. With an estimated average data breach cost of $202 per record1, or $4 to $20 million2 for recent hospital breaches -- hospitals must protect critical information from unauthorized access and use while at the same time sharing it at the point of care for diagnosis and coordination of patient care.

The proliferation of devices such as handhelds, laptops, tablets, carts and desktops—and applications—45 percent of hospitals manage more than 150 applications3 — adds to the complexity of the challenge and highlights the need for a solution. Hospital medical staffs can spend up to 60 minutes a day4 looking for the right workstation with the right applications to do their job. With labor accounting for almost 60 percent5 of hospital care costs and the costs to manage data breaches potentially running into the tens of millions of dollars, that's inefficiency that hospitals can no longer afford. Dell is helping members of the hospital staff work more efficiently by offering a virtual client solution that is easy for clinicians to use and IT teams to manage.

The News:

* Dell Mobile Clinical Computing (MCC) Simplifies Management for IT and Info Access for Medical Professionals and helps improve information security, staff productivity and care quality.
o Data Security: Patient info and applications are protected and managed centrally in the data center
o Hassle-free, Convenient Access: MCC enables access to role-based applications and data from any device anywhere in the hospital. Single sign-on, session roaming and location awareness simplify interaction for clinicians. Silver Cross Hospital's 1,000 medical professionals are saving up to one hour a day per professional with convenient access to the applications and info they need to do their jobs
o Simplified Management: Applications are updated in minutes instead of hours. Silver Cross Hospital cut update time from 80 hours/application to 20 minutes. IT manages digital identities in the data center, not mobile devices on the hospital floor
* Shift from Managing Devices to Managing Identities. MCC simplifies info security and management for IT and information access for medical professionals by locking applications and patient info in the data center and shifting IT focus from managing a growing number of end-user devices to managing user 'digital identities.' Digital identities are a combination of user profile, preferences, applications and privileges that give medical professionals authorized access to applications from any device anywhere in the hospital. Medical professionals perform rounds without hunting for patient paper records or the right device for the job.
* Right Infrastructure for the Job. Dell creates a practical blueprint for the design, implementation and management of a virtual client network that works for the medical professional and for the hospital with the right combination of thin client, virtual desktop, laptop or handheld. IT and medical professionals are no longer locked in to a 'one size fits all' model of client computing.
* A Complete Information-Sharing Solution for Hospitals. Dell is providing a complete solution from design, validation and implementation of the MCC infrastructure, to integration of clients, servers and software with training and 24/7 service and support.
* Managed/Hosted Services. Dell Services, which includes the former Perot Systems, provides end-to-end MCC services including management and hosting to assist clients with any operational scenario. Private cloud solutions can be deployed via traditional capital or utility based expenditure models to optimize resources consumed rather than building idle capacity.
* Availability. MCC is available to hospitals in the U.S. and in Europe.

Quotes:

'A proliferation of applications, passwords and end-user equipment throughout the hospital challenged our caregivers and complicated IT's trouble shooting and technical support. To increase the simplicity and reliability of our technology, we needed a new approach,' said David Hillenmeyer, CIO of Silver Cross Hospital, a 300-bed acute care facility located in Joliet, Illinois and a Top 100 Hospital National Award winner five years in a row.

'With MCC, we enjoy five-nines application availability. We can push application updates to these 200 desktops in 20 minutes; a huge savings from the 80 hours it took previously,' said Mr. Hillenmeyer. 'Shorter logins and access to a complete application suite on each workstation is helping our medical professionals reclaim nearly 20,000 hours for patient care this year alone. The solution's roaming capabilities have simplified physician and nurse rounding and documentation. Single sign-on coupled with the swipe cards and proximity detectors enforces password compliance and provides another level of access controls. These added protections help ensure Silver Cross' commitment to patient confidentiality and data security.'

'It's not enough to digitize patient information. We must make it available to medical professionals at the point of care, whether that's in a hospital or in an affiliated physician practice,' said Dr. Jamie Coffin, vice president, Dell Healthcare and Life Sciences. 'Dell is focused on transforming HIT to harness the power of information across our healthcare system to better coordinate and improve patient care and reduce its cost.'

___________________

1 Ponemon Institute: 'Annual Cost of Data Breach Report,' 2009

2 Credant: 'Data Security & Compliance in the Healthcare Market,' 2009

3 HIMSS: 'Healthcare and Integration Survey,' 2008

4 Dell Silver Cross Hospital Case Study, April, 2009

5 American Hospital Association: Trendwatch Chartbook 2009

— WebWireID108216 —

According to the ADA, the cost of diabetes care in the United States in 2007 was more than $174 billion, including $116 billion in excess medical expenditures attributed to diabetes and $58 billion in reduced national productivity. The ADA estimates that people with diabetes, on average, have medical expenditures that are approximately 2.3 times higher than the expenditures would be in the absence of diabetes and that approximately $1 in $10 health care dollars is attributed to diabetes. A significant portion of overall diabetes care costs, approximately $7 billion according to industry sources, is attributable to costs associated with monitoring blood glucose levels, and that market segment is projected to grow substantially by 2010 as patients and their physicians seek ways to manage glucose levels more effectively.

About Echo Therapeutics, Inc.

Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in acute and critical care. Echo's non-invasive Symphony tCGM System consists of its Prelude SkinPrep System, which incorporates patented and leading-edge skin ablation control technology, and wireless transmission and proprietary transdermal biosensor technologies. Echo's Symphony tCGM System is designed to provide both diabetes and hospital patients with a reliable, needle-free, easy-to-use, affordable and comfortable-to-wear continuous glucose monitoring device. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

The full special report on the company appears today at http://www.stockshaven.com/technical-trading-alert-for-echo-therapeutics-otcecte-ob/

Disclosure: Long ECTE

To feature your publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at michaelvlaicu@stockshaven.com or visit http://www.stockshaven.com/ir_contract/ for more info

###

About MiV Investments Inc.

MiV Investments Inc. can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.

For more financial and investment news, visit www.StocksHaven.com

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. StocksHaven.Com on behalf of MiV Investments Inc. does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

— WebWireID108169 —

Only about 1 in 4 Americans aged 50–64 regularly take advantage of preventive services such as screenings and immunizations, according to a report from the Centers for Disease Control and Prevention in collaboration with AARP and the American Medical Association (AMA).

The report, 'Promoting Preventive Services for Adults 50–64: Community and Clinical Partnerships,' focuses on opportunities to improve the health of the growing number of adults in the 50–64 age bracket to broaden the use of potentially lifesaving preventive services.

The report identifies recommended preventive services such as influenza vaccine, cholesterol screening, breast and cervical cancer screening, as well as preventive screenings for behaviors that could negatively impact health such as binge drinking.

'People aged 50–64 need access to preventive services to help them improve their overall health and to live vibrant, productive lives,' said CDC Director Thomas Frieden, M.D., M.P.H. 'CDC and our partners AARP and AMA are excited about this new resource because it enables our partners and others to more easily and effectively monitor improvements in health behaviors, screenings and immunizations. Our goal is to enhance the delivery and use of these recommended preventive services.'

By 2015, an estimated 63 million U.S. adults will be between the ages of 50 and 64, comprising 20 percent of the nation's population. They are at greater risk of developing chronic diseases such as heart disease and cancer than younger adults. Almost one–third of adults in this age group are uninsured or underinsured, which heightens the challenges of ensuring they receive critical preventive services.

Wayne Giles, M.D., M.S., director of CDC's Division of Adult and Community Health, and a member of the committee that prepared the report, emphasized the importance of addressing disparities in the use of preventive services. 'The racial and ethnic composition of adults in the United States is becoming more diverse. We must take this trend into

account as we promote the use of clinical preventive services to ensure that appropriate strategies are implemented to improve the health of all adults.'

The report describes proven, science–based strategies that highlight clinical and community efforts to promote the delivery of multiple or bundled preventive services. The report also highlights model programs, policies and strategies that communities can adopt, in concert with health care partners, to make sure services reach those in need. Calls to Action identify existing gaps and barriers in research, data and action, and highlight opportunities through model programs, policy and environmental strategies, and enhanced health tracking.

CDC's healthy aging program develops tools and programs designed to help older adults live longer, more productive and independent lives. By promoting health and disease prevention, CDC works to improve the quality of life of older adults and slow the expected growth of health care and long–term costs for this and future generations.

To view the full report and for more information about CDC's health aging activities visit www.cdc.gov/aging.

— WebWireID108191 —

Wide sections of the Southeast, Appalachia, and some tribal lands in the West and Northern Plains have the nation′s highest rates of obesity and diabetes, according to estimates released today by the Centers for Disease Control and Prevention. In many counties in those regions, rates of diagnosed diabetes exceed 10 percent and obesity prevalence is more than 30 percent.

The estimates, in this week′s Morbidity and Mortality Weekly Report, are the first to provide county–level snapshots of obesity across the United States. They also update diabetes county–level estimates released in 2008.

Eighty–one percent of counties in the Appalachian region that includes Kentucky, Tennessee, and West Virginia have high rates of diabetes and obesity. So do three–quarters of counties in the southern region that includes Alabama, Georgia, Louisiana, Mississippi, and South Carolina.

'Diabetes is costly in human and economic terms, and it′s urgent that we take action to prevent and control this serious disease,' said Dr. Ann Albright, director of CDC′s Division of Diabetes Translation. 'The study shows strong regional patterns of diabetes and can help focus prevention efforts where they are most needed.'

The estimates come from the agency′s Behavioral Risk Factor Surveillance System (BRFSS), which uses self–reported data from state–based adult telephone surveys, and 2007 census information. The information may help public health workers, health care providers, community organizations, and policymakers focus on high–risk regions to prevent type 2 diabetes and its complications as well as other chronic diseases linked to obesity, including heart disease, stroke, and some cancers.

The proportion of U.S. adults who are obese was 26.1 percent in 2008, according to BRFSS data. CDC estimates that nearly 8 percent of the population, or about 24 million people, have diabetes. Of these, 5.7 million are undiagnosed.

'The small–area estimates for obesity will be an important tool to help communities better understand and battle this serious public health problem. Communities are in the best position to prevent and reduce obesity among their citizens through innovative programs," said Dr. William H. Dietz, director of CDC's Division of Nutrition, Physical Activity and Obesity.

The medical costs of obesity reached an estimated $147 billion in 2008, and the medical costs of diabetes were $116 billion. People with diagnosed diabetes have medical costs that are 2.3 times higher than those without the disease.

Obesity is one of several factors linked to type 2 diabetes. Where people live, how much money they earn, their culture and their family history also play a role. An unhealthy diet, lack of physical activity, and socioeconomic factors contribute to both obesity and type 2 diabetes as well as to complications of diabetes. Some population groups also are at higher risk, including a number of racial and ethnic minorities.

CDC and its partners are working on a variety of initiatives to prevent type 2 diabetes and to reduce obesity. CDC has recommended 24 community strategies to prevent obesity, from providing greater access to healthy foods to redesigning communities to encourage more physical activity. The agency is also in a new partnership with state, federal, and nonprofit agencies targeting health disparities in Mississippi, which has the nation′s highest obesity rate and one of the highest rates of diabetes. CDC′s national diabetes prevention and control program provides resources and technical assistance to state health departments, national organizations, and communities.

To see county–level estimates of obesity and diagnosed diabetes, go to www.cdc.gov/diabetes/statistics. For more information on diabetes and preventing the disease, visit www.cdc.gov/diabetes. To learn more about CDC′s efforts in the fight against obesity or for more information about nutrition, physical activity, and maintaining a healthy weight, go to www.cdc.gov/obesity/index.html.

— WebWireID108185 —

The major objection from the CHMP was the lack of a comparator arm without Avastin in the BRAIN study, an investigational phase II trial. The CHMP tends to base its approval decisions on Phase III studies only. Roche decided to submit this data set to regulatory authorities globally based on Avastin's remarkable clinical activity seen in BRAIN. Roche remains convinced that the results of the BRAIN study, which were published in the Journal of Clinical Oncology in October 20091 are robust and remain valid. Adverse events in the BRAIN study were consistent with those previously seen with Avastin and no new safety signals were reported.1

'We are very disappointed with the CHMP opinion which will result in a delay to patients receiving an important new treatment option. We strongly believe that Avastin is a new treatment option for physicians within the EU which would bring hope to GBM patients and their families as it is today in the US and other countries,' said William M. Burns, CEO of Roche's Pharmaceuticals Division. 'Relapsed glioblastoma is a rare condition and represents a very high unmet medical need. These patients deserve effective additional therapies to manage this devastating disease. We remain committed to bringing Avastin to patients with newly diagnosed GBM in Europe'.

In May 2009 Avastin was granted accelerated approval for the treatment of GBM patients with progressive disease following prior therapy from the US Food and Drug Administration (FDA) based on data from the BRAIN study (AVF3708g) and an NCI study (NCI 06-C-0064E). Switzerland and ten other countries have already recognised the significant clinical benefits Avastin offers to GBM patients by giving approval.

Roche continues to further explore the role of Avastin in GBM through various investigator-led studies. In addition, a large phase III study (AVAGLIO) in over 900 patients with newly diagnosed GBM is currently underway with the aim of a global filing5.

Avastin has proven survival benefits across several types of cancer. It is approved in Europe for the treatment of the advanced stages of four common types of cancer: colorectal cancer, breast cancer, non-small cell lung cancer (NSCLC) and kidney cancer. These types of cancer collectively cause over 2.5 million deaths each year6,7,8. Over half a million patients have been treated with Avastin so far.
About Glioblastoma

Glioma is the most common type of primary brain tumour, accounting for approximately one third of all cases diagnosed9. Glioma also represents around 80% of all primary malignant brain tumour cases9. Glioblastoma (or glioblastoma multiforme; GBM) is the most common and the most aggressive type of glioma9. The prognosis for patients with GBM is poor. The treatment options for GBM depend on many factors including the location and size of the tumour, and the overall health and age of the patient10.

Glioblastoma affects approximately 17,000 people per year in the EU2. Following initial treatment, glioblastoma tumours nearly always return and currently, there are limited treatment options for patients when these relapses occur and their prognosis is particularly poor3. According to historical estimates, less than 10 percent of patients with recurrent GBM respond to treatment and approximately 15 percent will live six months without their disease getting worse1,5. GBM is a compelling therapeutic target for Avastin as these tumours have very high levels of vascular endothelial growth factor (VEGF)11.
About the BRAIN study (AVF3708g)

The BRAIN study was a US based open-label, multicentre, non-comparative phase II study including 167 patients with histologically confirmed GBM that had progressed following initial treatment with temozolomide and radiation. The primary endpoints of the BRAIN trial were progression free survival-6 (PFS-6), (defined as the percentage of patients who remained alive and progression free at 24 weeks) and objective response rate (ORR), (defined as a complete or partial response on two consecutive MRIs obtained 4 weeks apart). Secondary endpoints explored included OS, PFS, duration of response to treatment and safety. The BRAIN study evaluated Avastin at a dose of 10mg/kg every two weeks, as a single agent (BEV), or in combination with irinotecan chemotherapy (BEV-IRI).

The BRAIN study demonstrated that:

* When Avastin was evaluated as a single agent, the study showed that at six months over 40% (42.6%) of the patients were alive without their disease getting worse, as defined by PFS-6. When Avastin was combined with irinotecan, this figure increased to 50.3%1.
* In the study, over a quarter (28%) of patients responded to Avastin as a single agent, meaning tumours decreased in size by at least 50%. When Avastin was combined with irinotecan, 38% of patients responded to Avastin1.
* Patients receiving Avastin alone had a median overall survival of 9.2 months; this was 8.7 months for those receiving Avastin in combination with irinotecan, which was a secondary endpoint in the study1.
* Adverse events in the BRAIN study were consistent with those previously seen with Avastin and no new safety signals were reported1.
* Recent results showed the potential for additional positive impact on patients' daily lives. Of those patients who responded to Avastin-based therapy, a majority had a stabilisation or improvement in neurocognitive function at the time of the response and a reduction in their dose of steroids from baseline4.

About the AVAGLIO study

The AVAGLIO study is an international, multicentre, randomised, double blind, phase III study including over 900 patients with newly diagnosed histologically confirmed GBM which will investigate the efficacy and safety of treatment with Avastin combined with standard of care (temozolomide chemotherapy and radiotherapy) following surgery.

The primary endpoints of the AVAGLIO trial are progression free survival, (defined as the duration for which patient remains alive without their disease worsening) and overall survival. Secondary endpoints that will be explored include one and two year survival rates, safety and health related quality of life.
About Avastin

Avastin is an antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor). VEGF is a key driver of tumour angiogenesis – an essential process required for a tumour to grow and to spread (metastasize) to other parts of the body. Avastin's precise mode of action allows it to be combined effectively with a broad range of chemotherapies and other anti-cancer treatments. Avastin helps to control tumour growth and extend survival with only a limited impact on the side effects of chemotherapy.

Avastin has proven survival benefits across several types of cancer. It is approved in Europe for the treatment of the advanced stages of four common types of cancer: colorectal cancer, breast cancer, non-small cell lung cancer (NSCLC) and kidney cancer. These types of cancer collectively cause over 2.5 million deaths each year6,7,8. In the US, Avastin was the first anti-angiogenesis therapy approved by the FDA and it is now approved for the treatment of five tumour types: colorectal cancer, non-small cell lung cancer, breast cancer, brain (glioblastoma) and kidney (renal cell carcinoma).

Over half a million patients have been treated with Avastin so far. A comprehensive clinical programme with over 450 clinical trials is investigating the use of Avastin in various tumour types (including colorectal, breast, non-small cell lung, brain, gastric, ovarian, prostate and others) and different settings (advanced or early stage disease).
About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
1.Friedman H et al. J Clin Oncol 2009; 31 August [Epub ahead of print as doi/10.1200/JCO.2008.19.8721] Last accessed 1 September 2009 at http://jco.ascopubs.org/cgi/content/abstract/JCO.2008.19.8721v1.
2.Decision Resources, Cancer Incidence in 5 Continents Version IX, CI5 IX, World Population Prospects, Central Brain Tumor Registry of the United States, National Swedish Brain Tumour Registry
3.Medscape. Recurrent Glioblastoma Multiforme: Definition of Recurrent GBM. Last accessed 10 August 2009 at: http://www.medscape.com/viewarticle/540150_2
4.Vredenburgh, J. et al. ECCO 15 ESMO 34 2009; Abstract #8707.
5.Chinot, O. et al. ECCO 15 ESMO 34 2009; Poster #46
6.Garcia M et al. Global Cancer Facts & Figures. Atlanta, GA: American Cancer Society, 2007
7.WHO Cancer Factsheet N°297 – updated July 2008. Last accessed 24 March 2009 at http://www.who.int/mediacentre/factsheets/fs297/en/index.html.
8.Parkin DM et al. CA Cancer J Clin 2005; 55: 74-108.
9.Central Brain Tumor Registry of the United States (CBTRUS). Primary Brain Tumours in the United States Statistical Report.
10.Stupp R et al. Ann Oncol 2007; 18 (supplement 2): ii69–ii70.
11.Takano S et al. Cancer Res 1996; 56: 2185-2190.

— WebWireID108184 —

Raritan, NJ. Epilepsy and seizures affect nearly 3 million Americans of all ages and in 70 percent of new cases, no cause is apparent. Those who live daily with the condition have no way of knowing when the next seizure will occur, how long it will last or where they will be, often experiencing a roller coaster of emotions as they cope with the condition. The wonder behind the diagnosis, the perseverance in managing it, and the support received through family and friends are some examples of the stories told through artwork in the 2009 Expressions of Courage® art contest, a national art competition inviting people with epilepsy to submit creative artwork conveying their feelings of living with epilepsy.

Expressions of Courage® is a program developed and funded by Ortho-McNeil-Janssen Pharmaceuticals, Inc., in partnership with the Epilepsy Foundation. Today, they announced the winners of the 2009 contest which showcases the artistic talent and inspirational stories of people with epilepsy during National Epilepsy Awareness Month, recognized each November.

"Every year I look forward to announcing the Expressions of Courage® contest winners, as each individual has a unique way of demonstrating his or her feelings of living with the condition in a way that words cannot," said Eric R. Hargis, president and CEO of the Epilepsy Foundation. "We are truly proud of the Expressions of Courage® participants for giving a voice to what it's like to live with epilepsy, standing up and sharing their personal experiences with the public."

The 2009 contest winners include:

* Breanna Plessinger, 11, Covington, Ohio; In Plessinger's artwork titled, "Special," she drew a koala bear that represents one of the "special things" she enjoys while at epilepsy camp.
* Travis Johnson, 10, Houston, Texas; In Johnson's artwork titled, "Shadow," he showed his appreciation of his epilepsy service dog, Shadow, by creating a construction paper mosaic piece.
* Rhiannon Monroe, 14, Galveston, Texas; In Monroe's artwork titled, "The Red Dragon of Courage," the red dragon she drew represents courage in the face of epilepsy.
* Eliana Silbermann, 17, Memphis, Tenn.; In Silbermann's artwork titled "Jamais Vu," she visually represented one experience she encounters with her epilepsy condition called Jamais Vu, or deja vu.
* Richard Davis, 47, Spring Hill, Fla.; In Davis' artwork titled, "A Drop of Warmth in the Midst of Cold," he shows his solitary feelings in dealing with epilepsy through a cowboy, painted in water color, alone in the cold, yet who longs for warmth from others who have never experienced seizures.
* Timothy Minkley, 39, Waukusha, Wisc.; In Minkley's artwork titled, "Roaring Tiger," he captures the beauty, grace and fierceness of the animals he has painted, which reflect his perseverance in coping with epilepsy.
* Gabrielle Gati, 12, El Dorado, Ark.; In Gati's artwork titled, "Emotions in Color," she portrays her complex feelings about her epilepsy.
* Giovani Rodriguez Orraca, 10, Urb. Eldorado, Puerto Rico; In Rodriguez Orraca's artwork titled, "Muneca," he painted a doll during his time at epilepsy camp.
* Darla Renae Tobianski, 14, Dallas, Texas; In Tobianski's artwork titled, "Sunflower Days," she created a finger painting of three sunflowers, because she enjoys painting to express herself.
* Austin Kristof, 17, East Moline, Ill.; In Kristof's artwork titled, "Moving On," he demonstrates that he feels ready to "move on" now that his absence seizures have lessened.
* Katie Martin, 20, Perkiomenville, Pa.; In Martin's artwork titled, "The Yellow Finch," she painted a finch sitting on a tree branch, because she loves painting things in nature.
* Adam F. Snyder, 27, Forrest City, Ark.; In Snyder's artwork titled, "Angelic," he describes the people and blessings around him through art.

To view the 2009 contest artwork and learn about each artist's personal experience with epilepsy, visit www.ExpressionsofCourage.com. Winners were chosen by a panel of seven judges who based their selections on creativity and the ability to demonstrate their feelings of living with epilepsy through art. Panelists included:

* Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital
* Lillian Fitzgerald director of Fitzgerald Fine Art; curator of the Clinical Center Art Program at the National Institutes of Health and member of the Society of Arts in Healthcare
* Eric Hargis, Epilepsy Foundation president and CEO
* Jude Rouslin, of Sarasota, Fla., 2005, 2006 and 2008 Expressions of Courage® contest winner, an accomplished oil painter who shares her artwork through various displays
* Pamela Davis of Arcadia, Fla., 2004, 2005 and 2008 Expressions of Courage® contest winner, an accomplished artist who holds a leadership role with the Desoto County Arts and Humanities Council
* Bridget Bobinger, of Cincinnati, Ohio, 2007 Expressions of Courage® contest winner, holds a Masters in Art Education from Xavier University and volunteers frequently in art education
* Walter Danker, PhD, Manager, Professional Education, Ortho-McNeil-Janssen Pharmaceuticals, Inc.

— WebWireID108085 —

The 'Get Body Beautiful' program, which kicked off Nov. 1, is an interactive, multi-media program that includes: on-site community fitness classes at local malls and churches; radio programs; Internet-based tracking; and a dedicated Web site to help women track their progress.

'Get Body Beautiful' is the brainchild of Atlanta's Andrea Riggs, a national lifestyle and wellness expert. Her company, 'Body Beautiful,' a minority- and women-owned firm founded in 1998, helps women of color achieve better health through lifestyle, nutrition and fitness.

'The health disparities that exist in the African-American and Hispanic communities are simply unacceptable,' says Nancy Flake Johnson, president and CEO of the Atlanta Urban League. 'Whether you're talking about heart disease, diabetes, obesity or breast cancer, all of these conditions are preventable with proper nutrition and regular physical activity. The Atlanta Urban League is thankful for the Aetna grant and proud to partner with Andrea Riggs and 'Body Beautiful' to bring 'Get Body Beautiful' to women of color throughout the metro Atlanta area, because it's a fun and effective way to learn about nutritious delicious food, shopping and cooking techniques and strategies and to get physically active with other women who care about their health. And Andrea makes it so much fun we know we can help metro Atlanta women to engage in healthier lifestyles for themselves and their families with this program.'

'Body Beautiful' focuses on health and wellness campaigns for corporate and community groups, and produces high-energy, fitness content for TV and distribution. Riggs is a regular on the Atlanta business and social scene, the 'Atlanta's Biggest Loser' trainer on WXIA Alive, and contributes monthly to several national publications. She often trains celebrities and Atlanta's business executives, all while doing business and building the Body Beautiful and GET LEAN brands with leading corporations and consumers.

"With 78 percent of African American women overweight and at risk for major illnesses like heart disease and diabetes, this program equips women with the lifestyle and fitness tools they need to increase their physical activity and improve their health, feeling and looking good for life,' Riggs said.

'This is a dynamic, upbeat program that empowers African-American women to take control of their lives, improve their health and serve as positive role models for everyone they touch,' said Cynthia Follmer, president of Aetna's Georgia market. 'As a company that shares that passion for promoting wellness and healthy living, Aetna is proud to participate in this effort.'

Aetna provides health benefits to more than 600,000 members in Georgia.

— WebWireID108081 —

###

For business inquiries, please contact Chris Dowd, EVP Business Development, at (609) 896-4764 or email Chris.Dowd@pSellingSolutions.com.

About Publicis Strategic Solutions Group
Publicis Strategic Solutions Group (PSSG) aligns four high-performing Publicis message delivery companies—Publicis Selling Solutions, Scientific Voice, Pharmagistics, and Arista Marketing Associates—under one cohesive leadership team. PSSG provides a comprehensive array of multichannel message delivery solutions—from field teams to virtual representatives, and from speaker bureau management to sample compliance. More importantly, PSSG provides the power and intellect to create and implement a flexible, highly customized message delivery mix designed to match any product situation from prelaunch to late life cycle. Websites: www.pSellingSolutions.com, www.ScientificVoice.com, www.Pharmagistics.com, www.AristaMktg.com

About Publicis Healthcare Communications Group
Publicis Healthcare Communications Group (PHCG), a member of Publicis Groupe SA, is one of the largest healthcare communications groups in the world with over 2,700 employees located in 10 countries. Worldwide healthcare services include advertising, medical education, sales and marketing, and medical and scientific affairs. PHCG offers its clients a strategic partnership, a strong focus on ensuring value for their marketing spend, and exceptional performance on their assignments. Website: www.PublicisHealthcare.com

— WebWireID108070 —

As a solution, a Florida-based healthcare technology company has announced the launch of a new patent-pending, cellular and GPS-enabled mobile personal emergency response system (M-PERS) for seniors and those with special medical needs.

Headquartered in Boca Raton, Medical Mobile Monitoring has launched MobileHelp™, offering 24/7 medical and emergency monitoring services with real-time notification capabilities through the use of a GPS and cellular-enabled help button.

When subscribers need help, they simply press their help button and are connected via two-way voice to a central monitoring station that is live 24/7/365. By year's end, the new technology will also allow family members to see the location of their loved ones over the Web and be notified via mobile phone and email.

'MobileHelp addresses many of the limitations that exist with traditional medical alert systems currently on the market, namely the problem of the current technology only working in the home,' said Elias Janetis, founder and CEO of Medical Mobile Monitoring. 'Statistics show that 40% of fall-related injuries happen outside the home and only MobileHelp will have someone covered in these instances.'

'With our system, individuals are no longer confined to their homes and will have help when and where they need it with our anywhere help button,' he added.

The patent-pending technology has taken nearly four years to develop and gives peace-of-mind to family members and caregivers. The product is beneficial for those who desire to live independently and need access to emergency assistance at the touch of a button, no matter their location.

Medical Mobile Monitoring offers its product through a subscription-based service that requires a small monthly monitoring fee. Cost for the service and unit are comparable to the older products that are currently on the market.

'We are able to deliver significantly more features for about the same cost or less as the older in-home technology,' said Janetis. 'MobileHelp is a cost-effective way to significantly improve the quality of life of individuals and their families.'

In addition to its GPS medical alert system, Medical Mobile Monitoring also offers ClassicHelp, a traditional in-home medical alert system.

The company is currently offering free activation and a free month of service to anyone upgrading from a traditional alert system through year's end.

For more information, visit http://www.mobilehelpsys.com or call 1-877-827-6207.

# # #

— WebWireID108034 —

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. (Power3) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and Parkinson's disease. In the area of neurodegenerative diseases and breast cancer, Power3 has completed research and clinical validation studies involving over 1,500 patient samples. Power3 uses biostatistical analysis to monitor appropriate panels of biomarkers for diagnostic sensitivity and specificity for disease, normal and disease controls. By testing patient body fluids and tissues, including blood serum (for breast cancer and neurodegenerative diseases), and bone marrow aspirates (for leukemia patients), the Company has discovered protein biomarker patterns in over 1,500 patient samples that cover a range of diseases.

The full special report on the company appears today at http://www.stockshaven.com/power3-investors-feeling-bullish-prior-to-expo-otcpwrm/

Disclosure: Long PWRM

To feature a publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at michaelvlaicu@stockshaven.com or visit http://www.stockshaven.com/ir_contract/ for more info

###

About MiV Investments Inc.

MiV Investments Inc. can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.

For more financial and investment news, visit www.StocksHaven.com

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. StocksHaven.Com on behalf of MiV Investments Inc. does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

— WebWireID107965 —

Obtaining drug particle size information in respiratory products is important to understand the deliverable drug load, respirable fraction, and overall quality as well as from a cost perspective. Prior to entering clinical trials, this additional data can provide invaluable information, raising confidence and lowering risk of failure in vivo biostudies. The value and importance of gaining this information before taking the expensive step of beginning clinical development cannot be emphasised enough.

'We are excited to be able to provide our customers with information that can both improve the quality of their respiratory products as well as save them time and money in the long run,' said Dr. Thomas Voigt, Executive Vice President of ChemImage Corporation.

The technique uses ChemImage's unique technology combination of Raman chemical imaging, optical microscopy, and semi-automated data gathering and analysis software to identify particles based on their unique chemistry (for example, active pharmaceutical ingredient(s) versus excipients) as well as to analyse the particle size distribution in one step. Chemical information is based on the component chemistry identified by the unique Raman signature. This technique addresses the need for a fundamental understanding of API particles in the presence of other undissolved excipients in the formulation and can be used to study ISPS, aggregation and dispersion characteristics.

'We see a growing trend in the pharmaceutical industry of orally inhaled and nasal drug products with more than one active pharmaceutical ingredient,' said Dr. Voigt. 'In this case, morphological indications will not be enough to identify chemistry of particles in these formulations. Raman chemical imaging provides a much more objective method for ingredient-specific particle sizing.'

As one of the premiere meeting venues for the inhalation community, DDL provides an avenue for ChemImage to interface with researchers and business representatives regarding their product development challenges. ChemImage will be available at booth #9 to discuss chemical imaging product and service offerings.

About ChemImage
ChemImage Corporation is a world leader in Chemical Imaging technologies, providing laboratory services, instrumentation, software and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Our state-of-the-art Chemical Imaging technology can help to reveal critical chemical and biological information about processes, products and services.

— WebWireID108005 —

The researchers sequenced the exons and potential regulatory elements of 622 genes distributed across the genome that are candidate intervals for playing a role in healthy aging. They also included three contiguous genomic intervals containing variants associated with age-related diseases for a total of 3.6Mb using only standard molecular biology equipment and the Agilent SureSelect Target Enrichment System. They were able to call known SNPs with 99.7% accuracy, as well as tens of novel variants, the vast majority of them heterozygotes.

The researchers performed the sequencing on an Illumina Genome Analyzer and used SureSelect capture probes in-solution manufactured by Agilent Technologies for target enrichment. The findings are published in the on-line journal GenomeBiology, and can be accessed at http://genomebiology.com/content/pdf/gb-2009-10-10-r116.pdf

The article states that, in recent years, genome-wide association studies have identified "compelling" associations between more than 350 locations along the human genome and common complex traits. But a much larger number of samples must be analyzed to move beyond statistical associations to pinpoint the exact causes of these traits. The article explains that current methods of DNA sequencing cost too much for such large-scale population studies.

The authors write, "Next-generation sequencing technologies and their increased capacity have made it feasible to efficiently sequence hundreds of megabases of DNA. However, the current costs for sequencing entire human genomes make this approach prohibitively expensive for population studies."

"SureSelect is a very scalable capture method," said Olivier Harismendy, Ph.D., project scientist at the Moores UCSD Cancer Center. "It allows you to process multiple samples simultaneously. All you need is already in your lab: a 96-well plate, a magnet and a multichannel pipetter, and here is your high-throughput."

"The product we tested is very mature and the uniformity of the capture went up when compared to the proof-of concept experiment published earlier this year," said Kelly Frazer, Ph.D, Professor and Chief, Division of Genome Information Science, Pediatrics. "In the end, this comes out to less sequencing for an increased sensitivity to detect variants. With these experiments, we now understand better the impact of probe design and tiling frequency which are key parameters to improve capture uniformity and SNP calling."

"We were thinking about improving the economics of very large scale, automated studies from the very first days of SureSelect Target Enrichment, and it's gratifying to see investigators accomplish this without compromising accuracy or reproducibility," said co-author Emily LeProust, Ph.D., Agilent R&D Chemistry and Genome Partitioning program manager.

The conclusion is that the solution-hybridization-based method can generate highly uniform coverage of sequence targets that is reproducible across a large number of samples. This means that large-scale population studies using next-generation sequencing could become economically feasible, fueling breakthroughs in health research.

More information about Agilent SureSelect Target Enrichment System is available at www.opengenomics.com/SureSelect.
About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 17,000 employees serve customers in more than 110 countries. Agilent had net revenues of $4.5 billion in fiscal 2009. Information about Agilent is available on the Web at www.agilent.com.

About Moores UCSD Cancer Center

The Moores UCSD Cancer Center is one of the nation's 40 National Cancer Institute-designated Comprehensive Cancer Centers, combining research, clinical care and community outreach to advance the prevention, treatment and cure of cancer. For more information, visit http://health.ucsd.edu/cancer

— WebWireID107987 —

"Heart failure is one of the most costly medical conditions in the world, with 37 percent of U.S. Medicare dollars alone spent on heart conditions each year," said Michael Warmuth, senior vice president, diagnostics products, Abbott. "Novel markers like galectin-3 have the potential to make important contributions to improving patient and economic outcomes as we work to better understand this deadly and costly disease."

Galectin-3 is a protein that plays an integral role in the biological functions related to the initiation and progression of cardiac fibrosis and scarring which is a leading cause of heart failure (HF). Several studies have shown that galectin-3 may provide valuable insight about heart failure and its underlying disease processes.

"This development and commercialization partnership with Abbott is an exciting opportunity to explore a promising diagnostic test with broad applicability in cardiovascular disease on a leading laboratory platform," said Pieter Muntendam, MD, president and CEO of BG Medicine. "BG Medicine's strong life science discovery research program combined with Abbott's scientific and development leadership will enable us to bring important new tests to patients and laboratories."
About Abbott Diagnostics

Abbott Diagnostics is a global leader in in vitro diagnostics, with expertise in cardiac, metabolic and renal testing. Abbott's comprehensive portfolio of cardiac tests includes biomarkers that help thousands of labs and doctors around the world to diagnose and assess heart failure and myocardial infarction. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers quick processing of results, automation, convenience, cost effectiveness and flexibility.
About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine's proprietary technology platform enables rapid and cost-effective discovery of new high-value diagnostics biomarkers over a broad range of therapeutic areas. More information regarding BG Medicine is available on the company's Web site at www.bg-medicine.com
About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

ARCHITECT, i1000SR and i2000SR are trademarks of Abbott Laboratories.

— WebWireID107986 —

COPD is a chronic lung disease associated with a high level of mortality. According to the latest World Health Orgainzation (WHO) estimates, 210 million people suffer from COPD and it currently ranks as the fourth leading cause of death. However, the WHO predicts that it will become the third leading cause of death worldwide by 2030.1 In 2005 COPD was estimated to have killed over 3 million people2 – more than HIV/AIDS or lung and breast cancer combined.1,3 Despite this, COPD remains a scarcely known, under-diagnosed and under-treated disease that demands a changed approach to diagnosis and treatment.4 Fewer than half of patients with the condition have a proper diagnosis and only 35% of patients receive a regular prescribed medication.5,6

These issues, among others, have been highlighted by EFA who collected European data for the first time from patient groups` perspectives and are now calling for more to be done to reduce the burden of COPD and improve patient care. Over 11 million Europeans are affected by COPD and face its debilitating consequences on a daily basis.7

EFA`s book recognises that even in its early stages, COPD has a devastating impact on patients` quality of life as it begins to damage the lungs irreversibly causing sufferers to struggle for breath and with simple daily tasks.8 In addition, patients are frustrated about the difficulty in gaining effective management of their condition including early diagnosis, education, support services and access to the best treatments available. The goal of EFA`s efforts in the coming months will be to reduce the impact of COPD on patients and their caregivers and to focus efforts on a call to action for real improvements.

BI and GSK, who sponsored the project, support EFA`s conclusion that there is an urgent need for a coordinated strategy of advocacy both at European and national level. To improve overall COPD management, the following four areas of focus were identified:

* Increase the awareness of the public at large about COPD, its symptoms and risk factors in order to prevent the disease and to encourage sufferers to seek early diagnosis
* Raise the priority of COPD with policy makers to encourage the creation of screening guidelines and mandates for early diagnosis and management of the disease
* Improve the access to care and management for diagnosed COPD patients
* Safeguard the respiratory health of future generations.

Notes to Editors
The development and publication of the EFA Book on COPD in Europe: Sharing and Caring has been funded by an educational grant from Boehringer Ingelheim and GlaxoSmithKline. It aims to: Inform policy makers (EU and national) about COPD thereby prompting action where necessary Encourage healthcare professionals to collaborate with patient organisations to increase diagnosis, assessment and treatment of COPD patients Raise the awareness and prioritisation of this disabling disease.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world`s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of 11.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

GlaxoSmithKline – one of the world`s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

References:
1 World Health Organization. Immunizations, Vaccines and Biologicals Available from: http://www.who.int/immunization/topics/hiv/en/index1.html (last accessed 12th November 2009).
2 World Health Organization. COPD Available from: http://www.who.int/respiratory/copd/en/(last accessed 2nd November 2009).
3 World Health Organization. Factsheet 297 Cancer Available from: http://www.who.int/mediacentre/factsheets/fs297/en/ (last accessed 12th November 2009).
4 Wouters EFM. Economic analysis of the Confronting COPD survey: an overview of results. Respiratory Medicine 2003; 97:S3-S14.
5 Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance. United States, 1971-2000. MMWR Surveill Summ 2002; 51: 1-16.
6 National Library for Health. National Knowledge Week for COPD 2008 – Raising awareness of lung disease. http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278341. Accessed 22 October 2008.
7 World Health Organization. Global Burden of Disease Report 2004. Part 3. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part3.pdf (last accessed 12th November 2009).
8 World Health Organization. Factsheet 315 Chronic Obstructive Pulmonary Disease (COPD) Available from: http://www.who.int/mediacentre/factsheets/fs315/en/index.html (last accessed 2nd November 2009).

— WebWireID107982 —

* Data also show that Novartis MF59® adjuvant was well tolerated and could potentially quadruple the Novartis A(H1N1) 2009 influenza vaccine supply

* MF59® adjuvant has an established safety profile supported by clinical data from more than 33,000 study participants and 12 years of real life safety data with more than 45 million doses of influenza vaccine administered since 1997 in Europe

Basel - Novartis announced today new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the company's influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved US dose, fulfilled immune response criteria associated with protection in adults and the elderly (mote than or equal 65 years of age).

The data also showed a single 3.75µg dose of MF59-adjuvanted A(H1N1) 2009 vaccine met serologic protection criteria against influenza A(H1N1) in children ages 3 to 8, adults ages 18 to 64, and the elderly. All A(H1N1) 2009 influenza study vaccines were manufactured using the Novartis established seasonal Fluvirin® manufacturing platform. Novartis has discussed these new data with the US Food and Drug Administration (FDA) and is performing additional statistical analysis suggested by the agency. It is still under evaluation whether the antigen content per dose can be reduced in the US.
Current US guidelines for A(H1N1) 2009 vaccine use state that adolescents, adults and the elderly are required to receive one 15µg dose to achieve adequate protective antibody levels against the A(H1N1) virus, and children 9 years of age and under are required to receive two 15µg doses four weeks apart.

"These promising data suggest that many more people could potentially be vaccinated with our current vaccines supply, protecting more people earlier against the current pandemic," said Andrin Oswald, CEO of Novartis Vaccines and Diagnostics. "The data also confirms the antigen sparing potential of our proprietary adjuvant, MF59®. The vaccines output of our Liverpool, U.K., based flu manufacturing facility, fully dedicated to the US since the emergence of the pandemic, could be quadrupled if vaccines are adjuvanted."

These interim data were generated from pivotal clinical studies designed to evaluate the immunogenicity, safety and reactogenicity of both MF59-adjuvanted and unadjuvanted, inactivated novel swine origin A(H1N1) 2009 monovalent subunit influenza virus vaccine in 4,080 US subjects. In the pediatric trial, the findings are based on 80% of first dose data from 1,360 subjects ages 3 to 8 at day 22. In the adult trial, the findings are based on 95% of first dose data at day 1 and day 8 and approximately 40% of first dose data at day 22 from 1,360 adult subjects and 1,360 elderly subjects. Second dose data and data in ages 6-36 months of age are expected in December 2009.

About MF59

Novartis proprietary MF59 adjuvant has an established safety profile, supported by more than 12 years of clinical safety data and more than 45 million doses of commercial use in Europe. The adjuvant has been studied in clinical trials involving more than 33,000 people, including children, and has been licensed for use in people 65 years of age and over in the seasonal influenza vaccine Fluad® since 1997 in the European Union. Novartis also produces two A(H1N1) vaccines, Focetria® and Celtura®, which contain MF59 and are available outside the US. Currently, there are no approved vaccines in the United States that contain MF59.

Novartis has been contracted by the US Department of Health and Human Services (HHS) to produce 90 million doses of MF59 by the end of November.[1]

About A(H1N1) 2009 Vaccine

Novartis influenza A(H1N1) 2009 monovalent vaccine, manufactured using the established seasonal Fluvirin platform, is an inactivated influenza virus egg-derived vaccine indicated for active immunization of persons 4 years of age and older against influenza disease caused by pandemic A(H1N1) 2009 virus. The vaccine was approved by the FDA on September 15, 2009 as an unadjuvanted 15µg dose.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "may," "suggest," "could," "potentially," "promising," "potential," "expected," or similar expressions, or by express or implied discussions regarding regarding potential additional marketing approvals for Novartis' A(H1N1) vaccines and adjuvants, potential new indications or labeling for Novartis' A(H1N1) vaccines and adjuvants, potential future deliveries of influenza vaccines and adjuvants, or regarding potential future revenues from Novartis' A(H1N1) vaccines and adjuvants. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Novartis' A(H1N1) vaccines and adjuvants to be materially different from any future results, performance or achievements expressed or implied by such statements. Novartis' A(H1N1) vaccines will achieve any additional marketing approvals. Nor can there be any guarantee that Novartis' A(H1N1) vaccines and adjuvants will be approved for any additional indications or labeling in any market. Nor can there be any guarantee that Novartis will successfully meet its delivery obligations for its A(H1N1) vaccines and adjuvants. Neither can there be any guarantee that Novartis' A(H1N1) vaccines and adjuvants will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Novartis' A(H1N1) vaccines and adjuvants could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected manufacturing difficulties or delays, including continued unexpected difficulties with seed virus yields, and unexpected difficulties with our flu cell culture manufacturing facility and processes; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in each of these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

References
[1] This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHS100200800072I.

— WebWireID107891 —

Investors have begun to feel a renewed sense of optimism towards the company on the eve of their recent press release. Sinobiopharma announced that 23 generic drugs for which the Company has production rights are listed in China's National Essential Drugs List, which covers pharmaceuticals used to treat up to 80 percent of the most common diseases in China.

According to the Chinese government's healthcare reform plan, 90 percent of China's citizens will be covered by a universal healthcare system by the year 2010. Under the plan, drugs on the National Essential Drugs List (the 'List') will be purchased by various levels of government first, then distributed to medical facilities. All drugs on the List will be covered by the basic insurance plan supported by the government. The plan also calls for medical facilities to be upgraded, which includes the construction of 30,000 new hospitals, clinics and care centers across China.

Dr. Lequn Lee Huang, Sinobiopharma President and CEO was also quick to point out that, 'We expect that this new advantage in the marketplace will also enable the Company to enhance our ability to improve return on investment for shareholders in 2010.'

The news comes at an opportune time, as the company managed to post its first overall net profitable quarter since the Q2 2008. ('bout time!)

* Revenues increased to US $1,293,764 for the three months ended August 31, 2009, from US $931,203 in the corresponding period in 2008. This is an increase of 39%.
* Gross profit increased 57% to US $962,923, reflecting a 74% gross margin for the three months ended August 31, 2009.
* An overall net profit overall of US $237,167 for the three months ended August 31, 2009, marks the first time that Sinobiopharma has moved to net profitability in more than a year.

The full special report on the company appears today at http://www.stockshaven.com/bullish-technical-breakout-alert-otcsnbp-ob/

Disclosure: Long SNBP

To feature a publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at michaelvlaicu@stockshaven.com or visit http://www.stockshaven.com/ir_contract/ for more info

###

About MiV Investments Inc.

MiV Investments Inc. can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.

For more financial and investment news, visit www.StocksHaven.com

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. StocksHaven.Com on behalf of MiV Investments Inc. does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

— WebWireID107875 —

'If we can help a few people out by providing useful medical information, then it pays for itself,' said Dr. Joseph Cilea, Advanced Wellness Center owner and lead practitioner. "Dr. Yen has developed an innovative patient approach for those who suffer from acute or chronic pain. His commitment to the relief of pain by using interventional pain management is one of the newest and most exciting specialties in medicine for managing back and neck pain. The launching of NJCSPM on-line will make it easier for patients in Monmouth County, New Jersey find effective medical assistance for these types of pain."

The New Jersey Center of Spine and Pain Management (NJCSPM) at Advance Wellness is an accredited pain medicine, rehabilitation, and pain management medical center and a division of the New Jersey Advanced Wellness Center. Medical director of Advanced Wellness, Gary L. Yen, M.D. is board certified in Physical Medical Medicine & Rehabilitation and Pain Medicine. Dr. Yen grew up in Long Island, NY and subsequently received his medical degree from Ross University.

He completed his intern-ship in Internal Medicine at Lutheran Medical Center in Brooklyn, NY and residency in Physical Medicine and Rehabilitation at Stony Brook University. Dr. Yen went on to complete a pain medicine fellowship at Rehab NY in Buffalo, NY. During his fellowship training, he was the assistant athletic trainer to the Buffalo Bison which is the minor league AAA baseball team for the Cleveland Indians and the Niagara University Men's and Women's Collegiate Hockey team. Dr. Yen is a member of the American Academy of Physical Medicine & Rehabilitation, New Jersey Society of Physical Medicine & Rehabilitation, and the International Spine Intervention Society. He was also awarded Top Physician in New Jersey in 2008.

At NJCSPM, Dr. Yen focuses on the diagnosis and treatment of patients with joint, muscle, nerve, spine and sports related pain and works closely with his patients to achieve maximum pain relief to enhance quality of life. He provides patients with an individual program of integrated pain management therapies, drawing on his expertise in pain medicine and the wide range of treatments available. Dr. Yen has successfully treated thousands of patients without the use of surgery.

Dr Yen offers a full range of treatments for acute and chronic pain, including interventional spine procedures, electrodiagnostic studies, manipulation under anesthesia, trigger point injections, joint injections, epidural steroid injections, facet joint injections, sacroiliac steroid joint injections, medial branch blocks, radiofrequency neurolysis, discography, lumbar endoscopic discectomy, and spinal cord stimulation.

For additional information about the New Jersey Center for Spine& Pain Management visit http://www.newjerseypainmanagement.net/

For more information about Dr. Gary L. Yen please visit: http://www.newjerseypainmanagement.net/painrelief/

— WebWireID107812 —